Skip to main content
Stephen Sallan, MD, Hematology, Boston, MA, Dana-Farber Cancer Institute

StephenESallanMD

Hematology Boston, MA

Hematologic Oncology

Professor of Pediatrics, Dana-Farber Cancer Institute

Dr. Sallan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sallan's full profile

Already have an account?

Education & Training

  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1973 - 1975
  • Children's Hospital
    Children's HospitalFellowship, Child and Adolescent Psychiatry, 1972 - 1973
  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaResidency, Pediatrics, 1968 - 1969
  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterInternship, Transitional Year, 1967 - 1968
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 1967

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1971 - 2025
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Pediatric Oncology Award American Society of Clinical Oncology, 2015
  • Boston Red Sox Biomedical All-Star 2003
  • Boston Magazine Castle Connolly, 2008-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort
    Stephen E. Sallan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • How I Treat Acute Lymphocytic Leukemia: Insight From the Experts 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALL
    Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALLJune 10th, 2013
  • Intensified Chemotherapy Shows Promise for Children with Very High Risk Form of Leukemia
    Intensified Chemotherapy Shows Promise for Children with Very High Risk Form of LeukemiaDecember 10th, 2012
  • It Takes a Lifetime to Survive Childhood Cancer
    It Takes a Lifetime to Survive Childhood CancerOctober 17th, 2023

Grant Support

  • Clinical Consortia (Pediatric &Adult)National Cancer Institute2006–2010
  • Therapeutic Index Of Acute Lymphoblastic LeukemiaNational Cancer Institute2000–2010
  • Enhancing Treatment Outcomes In Childhood Acute Lymphocytic LeukemiaNational Cancer Institute2000–2002
  • Core--Acute Lymphocytic Leukemia ConsortiaNational Cancer Institute2000–2002
  • Fibroblast Growth Factor Quantification In ChildrenNational Center For Research Resources1996–2002
  • Enhancing Treatment Outcomes In Childhood AllNational Cancer Institute1996–1999
  • Core--All ConsortiumNational Cancer Institute1996–1999
  • Maximizing The Therapeutic Index Of Childhood AllNational Cancer Institute1995–1999
  • Pediatric Oncology GroupNational Cancer Institute1986–1991

Professional Memberships

Hospital Affiliations